|Ms. Lisa A. Conte||Founder, CEO, Pres & Director||525.21k||N/A||1959|
|Mr. Jonathan S. Wolin CPA, J.D., M.B.A.||Chief of Staff, Chief Compliance Officer & Gen. Counsel||336.51k||N/A||1962|
|Dr. Steven R. King||Chief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.||332.23k||N/A||1958|
|Ms. Carol R. Lizak||Chief Financial Officer||N/A||N/A||1964|
|Dr. Pravin R. Chaturvedi Ph.D.||Chair of Scientific Advisory Board & Acting Chief Scientific Officer||N/A||N/A||1963|
|Mr. Peter Hodge||Sr. Director of Investor Relations, Bus. Devel. & Special Events||N/A||N/A||N/A|
|Mr. David Sesin||Chief Manufacturing Officer||N/A||N/A||N/A|
|Mr. Ian H. Wendt M.B.A.||Chief Commercial Officer||N/A||N/A||N/A|
|Ms. Melissa A. Yeager J.D.||Sr. VP of Regulatory Affairs & Quality Assurance||N/A||N/A||1954|
|Dr. Michael K. Guy D.V.M., M.S., Ph.D.||VP of Preclinical & Nonclinical Studies||N/A||N/A||N/A|
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.